GSK plc 6-K, filed May 31, 2022
GSK plc (GSK)
6-K
2022-05-31
For: 2022-05-31
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on May 31, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 30 May 2022, London UK - LSE announcement
GSK announces further appointments to Designate Haleon
Board
Demerger and listing of Haleon expected in July 2022
GSK plc (LSE/NYSE: GSK) has today announced the appointments of
Asmita Dubey, Marie-Anne Aymerich and Bryan Supran to the Designate
Haleon Board, the new independent company to be formed following
the demerger of the GSK Consumer Healthcare business, expected in
July 2022.
These appointments follow the appointment of Sir Dave Lewis as
Non-Executive Chair Designate in December 2021 and the appointment
of six directors in March 2022 and complete the formation of the
Designate Haleon Board. This Board will benefit from an appropriate
mix of skills, experience, and diversity to support Haleon as a
listed company.
Sir Dave Lewis, Non-Executive Chair Designate, Haleon,
said: "We
are delighted to be welcoming Asmita, Marie-Anne, and Bryan as
Non-Executive Directors to the future Haleon Board. Together they
bring a strong understanding of the global consumer sector, as well
as relevant innovation and Asia experience. These appointments now
complete the Designate Board ahead of the demerger of Haleon from
GSK in July 2022. I look forward to working with our new board
colleagues."
Notes to Editors:
Creation of a new global-leading company in Consumer
Healthcare
The separation of GSK Consumer Healthcare, to form Haleon, is
subject to approval from shareholders and will be by way of a
demerger of at least 80% of GSK's 68% holding in the Consumer
Healthcare business to GSK shareholders (the Consumer Healthcare
business is a Joint Venture between GSK plc (GSK) and Pfizer, Inc.
(Pfizer), with GSK holding a majority controlling interest if 68%
and Pfizer holding 32%). Haleon shares are expected to attain a
premium listing on the London Stock Exchange with American
Depositary Receipts listed on the New York Stock
Exchange.
Haleon is strongly positioned to deliver better everyday health,
sustainable above-market growth, and attractive returns to
shareholders.
You can find out more here: https://www.gsk.com/en-gb/investors/a-new-consumer-healthcare-company/
Further to today's announcement, the complete Designate Haleon
Board is as follows:
●
Sir
Dave Lewis**, Non-Executive Chair
●
Brian
McNamara, Chief Executive Officer
●
Tobias
Hestler, Chief Financial Officer
●
Marie-Anne
Aymerich*, Non-Executive Director
●
Manvinder
Singh (Vindi) Banga*, Senior Independent Non-Executive
Director
●
Tracy
Clarke*, Non-Executive Director
●
Dame
Vivienne Cox*, Non-Executive Director
●
Asmita
Dubey*, Non-Executive Director
●
Deirdre
Mahlan*, Non-Executive Director
●
Bryan
Supran*, Non-Executive Director (Pfizer
nominee)
●
John
Young*, Non-Executive Director (Pfizer nominee)
* Indicates those persons who will become directors on
Admission.
**Sir Dave Lewis was appointed as a director of the company on 23
May 2022. His appointment as Non-Executive Chair takes effect on
Admission.
Appointment and selection process
An extensive search and selection process has been conducted for
Non-Executive appointments, including use of an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a
diverse list of candidates who were approached, evaluated, and
interviewed, against an agreed set of criteria, to identify the
most suitable candidates for appointment.
Asmita Dubey and Marie-Anne Aymerich are
expected to be determined to be independent Non-Executive Directors
of Haleon.
Bryan Supran has been nominated by Pfizer and will become a
Non-Executive Director.
Each Non-Executive Director will have a Letter of Appointment and
details of their fees will be provided in the Prospectus published
before demerger.
All appointments announced today will become effective from the
demerger.
Biographical details
Asmita Dubey
Asmita has over 25 years of experience working in consumer
businesses. She has worked at L'Oréal Group (L'Oréal)
since 2013 and is currently Chief Digital and Marketing Officer and
a member of the L'Oréal Executive Committee. Asmita brings
extensive expertise of marketing in the digital age and is leading
L'Oréal on a digital transformation journey to evolve the
marketing models, adopt new data-driven solutions, and accelerate
emerging business models for the largest beauty company in the
world. Asmita also brings strong experience working in China where
she strengthened L'Oréal's digital footprint in the region,
built L'Oréal's first joint-business partnerships with
Alibaba Group and Tencent Holdings Ltd and established a broader
start-up ecosystem. In addition to her executive career, Asmita
served on the GSK Consumer Healthcare Digital Advisory
Board.
Marie-Anne Aymerich
Marie-Anne has had a successful 30+ year international career
spanning the consumer and luxury sectors, growing businesses, and
shaping brands through innovation and creativity. Most recently,
Marie-Anne led the worldwide Oral Care category at Unilever PLC
where she developed a portfolio of new premium brands. Prior to
that Marie-Anne was Brand General Manager of LVMH Group's (LVMH)
Dior Perfume and Beauty business where she was responsible for
strategy, brand equity, innovation, advertising, and digital.
Before joining LVMH, Marie-Anne was Managing Director for
Unilever's Home and Personal Care business in France. Marie-Anne is
a non-executive director of Pierre Fabre Group and is a Trustee of
The Academy of Saint Martin in the Fields.
Bryan Supran
Bryan brings considerable corporate, strategic and business
development experience from over 25 years as a leading corporate
and transactional attorney across consumer healthcare,
pharmaceutical and life sciences. Since 2015, Bryan has served as
Senior Vice President & Deputy General Counsel of Pfizer, a
role that includes counselling management and the Board of
Directors on strategic initiatives and business development
transactions, such as Pfizer's COVID-19 vaccine collaboration with
BioNTech SE, the successful split-off of its animal health business
as Zoetis Inc., and the joint venture with GSK (of which he is a
director) to create the premier global consumer healthcare business
that will become Haleon. Bryan's role also has included leadership
of Pfizer's intellectual property and international legal teams, as
well as legal support for Pfizer's R&D and manufacturing
organizations. Previously, Bryan practiced law at Ropes & Gray
LLP in Boston and New York, where he helped establish the firm's
life sciences practice.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
Emma White
|
+44 (0) 7823 523562
|
(Consumer)
|
|
|
Rakesh Patel
|
+44 (0) 7552 484646
|
(Consumer)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
30, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|